Enteric-Coated Glucosinolates And Beta-Thioglucosidases
The present invention relates to a particulate composition comprising enteric-coated glucosinolate and beta-thioglucosidase particles. The present invention further provides a method of converting glucosinolate to isothiocyanate in the small intestine comprising orally administering to a subject an enteric-coated chemoprotectant precursor composition comprising enteric-coated glucosinolate and beta-thioglucosinodase particles. In another aspect, uncoated glucosinolate and beta-thioglucosinodase particles may be provided in an enteric-coated capsule. Preferably, the glucosinolate is glucoraphanin and the beta-thioglucosidase is myrosinase. The enteric coating targets the compound for release in the small intestine where beta-thioglucosinodase enzyme converts glucosinolate to chemoprotectant isothiocyanate.
1 . A method of converting glucosinolate to isothiocyanate in the small intestine comprising orally administering to a subject an enteric-coated chemoprotectant precursor composition, said method comprising:
(1) enteric-coated beta-thioglucosidase particles;
(2) enteric-coated glucosinolate particles,
wherein beta-thioglucosidase and glucosinolate are released from the enteric-coated beta-thioglucosidase particles and enteric-coated glucosinolate particles, respectively, in the small intestine where beta-thioglucosidase converts glucosinolate to isothiocyanate.
2 . The method of claim 1 , wherein the beta-thioglucosidase is myrosinase, the glucosinolate is glucoraphanin, and the isothiocyanate is sulforaphane.
3 . The method of claim 1 , wherein the enteric-coated chemoprotectant precursor composition further comprises enzyme activator from the group consisting of ascorbic acid and its derivatives, or a combination thereof.
4 . The method of claim 1 , wherein the beta-thioglucosidase particles and glucosinolate particles are formed by spheronization.
5 . The method of claim 1 , wherein the enteric-coated chemoprotectant precursor composition further comprises a coating excipient selected from the group consisting of microcrystalline cellulose and its derivatives, oat fiber, lactose, carboxy methyl cellulose, or a combination thereof.
6 . The method of claim 1 , wherein enteric-coated chemoprotectant precursor composition further comprises a diluent selected from the group consisting of lactose, starch, dextrin, water, glycerol, sorbitol, propylene glycol, or a combination thereof.
7 . The method of claim 1 , wherein the enteric coating is selected from the group consisting of shellac, calcium alginate, zein, fatty acids, fats, or a combination thereof.
8 . A method of converting glucosinolate to isothiocyanate in the small intestine comprising orally administering to a subject an enteric-coated capsule containing a chemoprotectant precursor composition comprising:
(1) beta-thioglucosidase particles;
(2) glucosinolate particles,
wherein beta-thioglucosidase and glucosinolate are released from the beta-thioglucosidase particles and glucosinolate particles, respectively, in the small intestine where beta-thioglucosidase converts glucosinolate to isothiocyanate.
9 . The method of claim 8 , wherein the beta-thioglucosidase is myrosinase, the glucosinolate is glucoraphanin, and the isothiocyanate is sulforaphane.
10 . The method of claim 8 , wherein the chemoprotectant precursor composition further comprises an enzyme activator from the group consisting of ascorbic acid and its derivatives, or a combination thereof.
11 . The method of claim 8 , wherein the beta-thioglucosidase and glucosinolate particles are formed by spheronization.
12 . The method of claim 8 , wherein the chemoprotectant precursor composition further comprises a coating excipient selected from the group consisting of microcrystalline cellulose and its derivatives, oat fiber, carboxy methyl cellulose, lactose, or a combination thereof.
13 . The method of claim 8 , wherein the chemoprotectant precursor composition further comprises a diluent selected from the group consisting of lactose, starch, dextrin, water, glycerol, sorbitol, propylene glycol, or a combination thereof.
14 . The method of claim 8 , wherein the enteric coating is selected from the group consisting of shellac, calcium alginate, zein, fatty acids, fats, or a combination thereof.
15 . An enteric-coated chemoprotectant precursor composition comprising:
(1) about 0.5 to about 50 weight percent glucosinolate;
(2) about 0.5 to about 50 weight percent beta-thioglucosidase; and
(3) about 1 to about 99 weight percent composition comprising coating excipient and optionally diluent,
wherein the chemoprotectant precursor composition is encapsulated with enteric coating.
16 . The enteric-coated chemoprotectant precursor composition of claim 15 , wherein the beta-thioglucosidase particles are myrosinase particles and the glucosinolate particles are glucoraphanin particles.
17 . The enteric-coated chemoprotectant precursor composition of claim 15 , further comprising about 0.001 to about 10 weight percent enzyme activator selected from the group consisting of ascorbic acid and its derivatives, or a combination thereof.
18 . The enteric-coated chemoprotectant precursor composition of claim 15 , wherein the coating excipient is selected from the group consisting of microcrystalline cellulose and its derivatives, oat fiber, carboxy methyl cellulose, or a combination thereof.
19 . The enteric-coated chemoprotectant precursor composition of claim 15 , wherein the diluent is selected from the group consisting of lactose, starch, dextrin, water, glycerol, sorbitol, propylene glycol, or a combination thereof.
20 . The enteric-coated chemoprotectant precursor composition of claim 15 , wherein the enteric coating is selected from the group consisting of shellac, calcium alginate, zein, fatty acids, fats, or a combination thereof.
21 . A food product comprising an effective amount of the enteric-coated chemoprotectant precursor composition of claim 15 .
22 . The food product of claim 21 , wherein the glucosinolate is glucoraphanin and the beta-thioglucosinolate is myrosinase.
23 . A pharmaceutical composition comprising an effective amount of the enteric-coated chemoprotectant precursor composition of claim 15 .
24 . The pharmaceutical composition of claim 23 , wherein the glucosinolate is glucoraphanin and the beta-thioglucosinolate is myrosinase.
25 . An enteric-coated capsule comprising a chemoprotectant precursor mixture, the chemoprotectant mixture comprising uncoated beta-thioglucosidase particles and uncoated glucosinolate particles in a ratio of about 1:100 to about 100:1, wherein the mixture is contained within an enteric-coated capsule.
26 . The enteric-coated capsule of claim 25 , wherein the beta-thioglucosidase is myrosinase and the glucosinolate is glucoraphanin.
27 . The enteric-coated capsule of claim 25 , wherein the chemoprotectant precursor mixture further comprises about 0.001 to about 10 weight percent enzyme activator selected from the group consisting of ascorbic acid and its derivatives, or a combination thereof.
28 . The enteric-coated capsule of claim 25 , wherein the chemoprotectant mixture comprises uncoated beta-thioglucosidase particles and uncoated glucosinolate particles in a ratio of about 1:10 to about 10:1.
29 . The enteric-coated capsule of claim 25 , wherein the enteric coating is selected from the group consisting of shellac, zein, fatty acids, fats, or a combination thereof.